Title : Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.

Pub. Date : 2019 Jun 15

PMID : 31047967






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 We aimed to establish a semi-physiologically based pharmacokinetic (semi-PBPK) model involving both enzyme and transporter turnover to simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 (CYP) 3A4/P-glycoprotein (P-GP) in human. Rifampin phosphoglycolate phosphatase Homo sapiens
2 Rifampicin was chosen as the CYP3A /P-GP inducer. Rifampin phosphoglycolate phosphatase Homo sapiens
3 Contribution of both CYP3A and P-GP induction in intestine and liver by rifampicin to pharmacokinetic profiles of victim drugs was investigated. Rifampin phosphoglycolate phosphatase Homo sapiens
4 DDIs of rifampicin with CYP3A or P-GP substrates following oral versus intravenous administration to human were successfully predicted using the developed semi-PBPK model. Rifampin phosphoglycolate phosphatase Homo sapiens